CD4 Monitoring in HIV Infected Patients not Eligible for Receiving ARV in 2004 - 2006

Authors

  • พีระมน นิงสานนท์ สำนักโรคเอดส์ วัณโรค และโรคติดต่อทางเพศสัมพันธ์
  • สมศักดิ์ ศุภวิทย์กุล Thailand MOPH - US CDC Collaboration
  • เสาวนีย์ สีสองสม ศูนย์ความร่วมมือไทย-สหรัฐด้านสาธารณสุข
  • ธนวงค์ บัวซ้อน Bureau of AIDS, Tuberculosis and STI
  • กิตติ นุชชม Bureau of AIDS, Tuberculosis and STI

Keywords:

CD4 cell monitoring, Asymptomatic patients, Median survival time before stating ARV, Health promotion in HV infected patient

Abstract

The objectives of this study was to encourage for continuously periodic CD4 count in asymptomatic patients. HIV infected patients who had been treated in 30 hospitals in Chiang Mai, Chiang Rai and Phayao whose CD4 count > 200 and had no symptom according to 506/1 report were recruited for the study. Classifying for CD4 count tests were as follows: every 6 month for patients with CD4 > 300, every 4 months for those with CD4 = 251 - 300 and every 2 months for those with CD4 = 200 - 250 cell/mm3. CD4 level monitoring and related variables such as patient's characteristic, basic health care information, sexual behaviors, opportunistic infections and other risk factors were collected for 2 years time. It was found that there were 2,140 HIV infected patients recruited in this study of which 1,525 cases were group A (CD4 > 300 cell/mm3 ); 319 cases were group B (250 < CD4 < 300 cell/mm3) and 296 cases were group C (200 < CD4 < 250 cell/mm3). About 63.6 % were female; the incident of opportunistic infections (OI) were 0.8/100PY and median survival time before starting ARV in was 14, 7 and 2 for the Group A, B and C respectively. Group A is significantly different from others (P < 0.05) but group B and C is not .(P = 0.85). Median CD4 of all samples who started ARV drug was 175.3 cell/mm3. 38.5% of HIV/AIDS patients participated as a member in Day Care Center and 51.0 % of HIV/AIDS patients who have sex with partner used condom every times. The advantages of CD4 monitoring project contain to increase CD4 level at starting ARV in HIV infected patients in order to reduce side effects of ARV using, and enhance the achievement of HIV treatment due to increasingly and easily access CD4 monitoring service. Including, HIV infected patients were educated and received treatment and care continuously to reduce risk factors.

References

1. Timothy, Sterling, Richard E, Claissob, Jeanne Kernly. Richard D,Moor .Improve outcomes with earlier of Highly ActiveAntiratroviral Therapy Among Human Immunodeficiency Virus-Infected Patients Who Achieve Durable Virologic Suppression :Long Follow-up of an observational Cohort Study. The Journal of Infectious Diseases. 2003; 188: 1659-1665

2 Hunt PeterW, Deeks StevenG,Rodriguez, Bening noC, ValdeZ Hernan C , Shade Starley B , etal. Continued CD4 cell countincreases in HIV infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003;
17(13) : 1907-1915

3. Kaufmann Gillbert R, Block Mark, Finlayson Robert , Zaunders John, Smith Don, Cooper David A. The extent of HIV-1-relatted immunodeficiency and age predict the long term CD4T lymphocyte response to Potent antiretroviral therapy. AIDS 2002; 16 (3): 359-367

4. Hans H. Hirsch, Gilbert Kaufmann, Pedram Sendi, Manual Battergay. Immune Reconstitution in HIV-Infected Patients. Clinical Infectious Diseases 2004; 38: 1159-1166

5. Panita Pathip vanich MD, Archawin Rojana wiwat MD, Koya Ariyoshi MD, Toshiyuki Miura MD, Wadchara Pumpradit MD, Suchint Wong choosie MD et al . Mortality Analysis of HIV-1 Infected Patients for Prigritizins Antiretroviral Drug Therapy. J Med Sssoc Thai 2004; 8: 951-4

6. Wood, Evan; Hogg, Robert S, Yip, Benita, Harrigan , P Rochard, O' Shaughnessy , Michael V Montaner, Julio SG. Is there a baseline CD4 cell count that precludes a survival response to modern antiretrpviral therpy. AIDS. 2003: 17(5): 711-720

7. Gilbert R Kaufmann, Nina Khanna, Rainer Weber, Luc perrin, Hansjakob Furrer, Matthias Cavassini. Long-term response to multiple Sequential regimens of highly active antiretroviral therapy for HIV infection . Antiretroviral therapy 2004; 9: 263 - 274

8. สัญชัย ชาสมบัติ, ชีวนันท์ เลิศพิริยสุวัฒน์, พรทิพย์ ยุคตานนท์. สำนักโรคเอดส์ วัณโรคและโรคติดต่อทางเพศสัมพันธ์ กรมควบคุมโรค. การรักษาโรคติดเชื้อ HIV/AIDS ในผู้ใหญ่: แนวทางการดูแลรักษาผู้ติดเชื้อเอชไอวีและผู้ป่วยโรคเอดส์เด็กและผู้ใหญ่ในประเทศไทย ปี พศ.2547. พิมพ์ครั้งที่ 1. กรุงเทพฯ; 2546: 89-180

9. Mustafa T, SY FS, Macera CA, et al. Association between exercise and HIV disease progression in a cohort of homosexual men. Ann Epidemiol. 1999: 9(2): 127-31

10. Vongsivalas Y, Yenrudi S. Lung cancer in AIDS/HIV infection. Chula Med J 2004

11. Holistic services and community involvement: the combined Chiang Rai day care center strategies. R Lolekha. Presented at the 7th ICAAP. Japan.

12. ธีรพล สุขมาก, อารีย์ สุภาวงศ์, เพียงใจ ตัณฑชน, ศุภลักษณ์ จิตนาธรรม. ประสิทธิภาพและผลข้างเคียงของการใช้ยาต้านไวรัสเอ็ชไอวีที่ โรงพยาบาลทุ่งสง. วารสารโรคเอดส์. 2548; 17: 60-72

13. Virus disease AIDS and Related disorders : in: Dennist L Kasper, Eugene Braunwald, Anthony S fauci, Stephan L. HAUSER, Dan L.Longo, J. Larry jameson. Harrison s principles of internal medicine. 16 thed. New York: Mc Graw Hill; 2005. 1076-1139

Downloads

Published

2008-03-31

How to Cite

1.
นิงสานนท์ พ, ศุภวิทย์กุล ส, สีสองสม เ, บัวซ้อน ธ, นุชชม ก. CD4 Monitoring in HIV Infected Patients not Eligible for Receiving ARV in 2004 - 2006. Dis Control J [Internet]. 2008 Mar. 31 [cited 2024 Mar. 29];34(1):11-2. Available from: https://he01.tci-thaijo.org/index.php/DCJ/article/view/155995

Issue

Section

Original Article